Thyrocare Q2 Profit Drops 68% To ₹15 Crore On Impairment Loss

29 Oct 2026, 9:07 pm · 2h ago · 1 min read · Inc42New

PharmEasy-owned diagnostic chain Thyrocare reported a 68.2% year-on-year drop in net profit to ₹15.2 crore for the second quarter, hit by an exceptional impairment loss of ₹45 crore on subsidiary Nueclear Healthcare. Operating revenue increased 25% year-on-year to ₹270.8 crore, driven by a 26% rise in diagnostic testing revenue to ₹256.7 crore. Without the one-off charge, profit before tax rose 25% to ₹77.8 crore. The company board has approved divesting its entire stake in Nueclear Healthcare to Trovera Healthcare for ₹141.4 crore to focus on its higher-margin pathology operations.